Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders

Kobyliak, Nazarii; Falalyeyeva, Tetyana; Kyriachenko, Yevheniia; Tseyslyer, Yuliya; Kovalchuk, Oleksandr; Hadiliia, Olena; Eslami, Majid; Yousefi, Bahman; Abenavoli, Ludovico; Fagoonee, Sharmila; Pellicano, Rinaldo

doi:10.23736/s2724-6507.22.03752-6

Cited by 19 publications

(14 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…muciniphila and insulin sensitivity in both humans and animals. 30 Thus, the amelioration of IR in GDM mice by XOS intervention is at least partly attributable to their abilities to proliferate Akk. muciniphila .…”

Section: Discussionmentioning

confidence: 99%

Xylooligosaccharides ameliorate insulin resistance by increasing Akkermansia muciniphila and improving intestinal barrier dysfunction in gestational diabetes mellitus mice

Yang,

Wang,

et al. 2024

Food Funct.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Xylooligosaccharides ameliorate insulin resistance by increasing Akkermansia muciniphila and improving intestinal barrier dysfunction in gestational diabetes mellitus mice

Yang,

Wang,

et al. 2024

Food Funct.

View full text Add to dashboard Cite

show abstract

“…It should be noted that the Firmicutes phylotype includes one of the main representatives of the obligate Lactobacillus , which plays a significant role in the formation of colonization resistance and stability of the gut microbiome. In addition, representatives of Firmicutes have a significant effect on the metabolic activity of the gut microbiota, taking part in the synthesis of short-chain fatty acids, including butyrate, thereby modifying the state of the intestinal mucosal barrier ( 33 , 34 ). The number of F. prausnitzii belonging to the family Ruminococcaceae, a member of the Firmicutes phylotype, is considered a regulatory and plays an important role in maintaining intestinal homeostasis, was also significantly reduced before treatment ( p < 0.05).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionGrowing evidence supports the effectiveness of fecal microbiota transplantation (FMT) in treating ulcerative colitis (UC), although its effects seem to depend on the method of introduction, the number of procedures, the donor material, and the severity of UC.AimThis study aimed to assess FMT's clinical and microbiological efficacy, tolerability, and safety in patients with mild-to-moderate UC.Material and methodsPatients with mild-to-moderate UC were randomized into two groups. The first group (standard-care, n = 27) was treated with basic therapy–mesalazine–at a daily dose of 3 g (2 g orally + 1 g rectally). In the second group (FMT group, n = 26), while taking mesalazine at the indicated dose, each patient with UC as add-on therapy underwent a single FMT procedure with fresh material delivered by colonoscopy from a healthy donor. The clinical efficacy of treatment in both groups was evaluated after 4 and 8 weeks. The primary outcome was remission of UC, defined as a partial Mayo score ≤2, and decreased fecal calprotectin. All patients underwent bacteriological examination of feces for quantitative microbiota composition changes.ResultsClinical response in the form of a significant decrease in stool frequency and a tendency to normalize its consistency after 4 weeks was detected in 14 (51.9%) patients of the standard care group and 16 patients (61.5%) of the FMT group (p = 0.583). The Mayo score in the standard care group was 3.59 ± 1.21 and in the FMT group−3.15±1.04 (p=0.166). After 8 weeks, the main primary endpoint was achieved in 70.4% of the standard-care group patients as compared to 84.6% of participants who received FMT as add-on therapy (p = 0.215). A more pronounced decrease in Mayo score was observed in the FMT group compared to the standard-care group (1.34 ± 1.44 vs. 2.14 ± 1.4; p = 0.045). All patients also showed a significant decrease in fecal calprotectin levels, which correlated with clinical data, stool frequency, and clinical remission. An improvement in gut microbiota composition was noted in both groups, albeit it was significantly more pronounced in the FMT group.ConclusionsFTM in patients with mild-to-moderate UC is a well-tolerated, effective, and safe method of treatment in comparison to basic therapy.Clinical trial registrationhttps://clinicaltrials.gov/ct2/show/NCT05538026?term=kobyliak&draw=2&rank=4, identifier: NCT05538026.

show abstract

“…SCFAs, such as acetate, butyrate, and propionate, are the end products of microbial fermentation of dietary fibers in the gut (ileum and colon) and represent 95% of the total SCFAs content in the intestine. Bacteria of different species could produce SCFAs using different biochemical pathways ( Table 2 ) [ [76] , [77] , [78] , [79] ]. The molar ratio of acetate, propionate, and butyrate production in the healthy colon is approximately 60:25:15, respectively [ 28 ].…”

Section: Microorganism Associated Molecular Patterns and Dcs Interactionmentioning

confidence: 99%

Microbiota substances modulate dendritic cells activity: A critical view

Shvets,

Khranovska,

Senchylo

et al. 2024

Heliyon

Self Cite

View full text Add to dashboard Cite

Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders

Cited by 19 publications

References 86 publications

Xylooligosaccharides ameliorate insulin resistance by increasing Akkermansia muciniphila and improving intestinal barrier dysfunction in gestational diabetes mellitus mice

Xylooligosaccharides ameliorate insulin resistance by increasing Akkermansia muciniphila and improving intestinal barrier dysfunction in gestational diabetes mellitus mice

Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial

Microbiota substances modulate dendritic cells activity: A critical view

Contact Info

Product

Resources

About